Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H1 2017’, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

– The report reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) therapeutics and enlists all their major and minor projects

– The report assesses Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics Sarl

Aeglea BioTherapeutics Inc

Affimed GmbH

Altor BioScience Corp

Amgen Inc

ARA Healthcare Pvt Ltd

Ariad Pharmaceuticals Inc

Array BioPharma Inc

Atara Biotherapeutics Inc

Bellicum Pharmaceuticals Inc

Bexion Pharmaceuticals LLC

Bio-Path Holdings Inc

BioSight Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Calithera Biosciences Inc

CanBas Co Ltd

Cantargia AB

Celgene Corp

Cellectar Biosciences Inc

Cellectis SA

Cellular Biomedicine Group Inc

Ceronco Biosciences

Cielo Therapeutics Inc

Constellation Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

Deciphera Pharmaceuticals LLC

Eli Lilly and Company

EpiZyme Inc

Erytech Pharma SA

Fate Therapeutics Inc

Formula Pharmaceuticals Inc

Gamida Cell Ltd

Gilead Sciences Inc

GlaxoSmithKline Plc

Humorigin Biotechnology Corp

iDD biotech SAS

Immunomedics Inc

Incyte Corp

Interprotein Corp

Jasco Pharmaceuticals LLC

Jazz Pharmaceuticals Plc

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kiadis Pharma NV

Kite Pharma Inc

Les Laboratoires Servier SAS

medac GmbH

Medivir AB

Merck & Co Inc

Mesoblast Ltd

Millennium Pharmaceuticals Inc

NantKwest Inc

NBE-Therapeutics AG

Nimbus Therapeutics LLC

Novartis AG

NovImmune SA

NuCana BioMed Ltd

Omeros Corp

OncoTartis Inc

OncoTherapy Science Inc

Oncternal Therapeutics Inc

Oribase Pharma

OSE Immunotherapeutics

Pfenex Inc

Pfizer Inc

Pharma Mar SA

Polyphor Ltd

Regeneron Pharmaceuticals Inc

Sanofi

Sareum Holdings Plc

Seattle Genetics Inc

Shire Plc

Sorrento Therapeutics Inc

Spectrum Pharmaceuticals Inc

Sun Pharma Advanced Research Company Ltd

SYNIMMUNE GmbH

Syros Pharmaceuticals Inc

Takara Bio Inc

Targazyme Inc

Threshold Pharmaceuticals Inc

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Tragara Pharmaceuticals Inc

Trillium Therapeutics Inc

Verastem Inc

VioQuest Pharmaceuticals Inc

Xbrane Biopharma AB

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview 8

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development 9

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment 36

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development 54

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles 106

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects 742

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products 746

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones 747

Appendix 763

List of Tables

List of Tables

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by 4SC AG, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by AbbVie Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Actinium Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ADC Therapeutics Sarl, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Aeglea BioTherapeutics Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Affimed GmbH, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Altor BioScience Corp, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Amgen Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ARA Healthcare Pvt Ltd, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Ariad Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Array BioPharma Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Atara Biotherapeutics Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bexion Pharmaceuticals LLC, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bio-Path Holdings Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by BioSight Ltd, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bristol-Myers Squibb Company, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Calithera Biosciences Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by CanBas Co Ltd, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cantargia AB, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Celgene Corp, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellectar Biosciences Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellectis SA, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellular Biomedicine Group Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Ceronco Biosciences, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cielo Therapeutics Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Constellation Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Eli Lilly and Company, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by EpiZyme Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Erytech Pharma SA, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Fate Therapeutics Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Formula Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Gamida Cell Ltd, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Gilead Sciences Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by GlaxoSmithKline Plc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Humorigin Biotechnology Corp, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by iDD biotech SAS, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Immunomedics Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Incyte Corp, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Interprotein Corp, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Jasco Pharmaceuticals LLC, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Jazz Pharmaceuticals Plc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Johnson & Johnson, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Juno Therapeutics Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Kiadis Pharma NV, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Kite Pharma Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Les Laboratoires Servier SAS, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by medac GmbH, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Medivir AB, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Merck & Co Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Mesoblast Ltd, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by NantKwest Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by NBE-Therapeutics AG, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Nimbus Therapeutics LLC, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Novartis AG, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by NovImmune SA, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by NuCana BioMed Ltd, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Omeros Corp, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by OncoTartis Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by OncoTherapy Science Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Oncternal Therapeutics Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Oribase Pharma, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by OSE Immunotherapeutics, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Pfenex Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Pfizer Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Pharma Mar SA, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Polyphor Ltd, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sanofi, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sareum Holdings Plc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Seattle Genetics Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Shire Plc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sorrento Therapeutics Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Spectrum Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by SYNIMMUNE GmbH, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Syros Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Takara Bio Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Targazyme Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Threshold Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Tolero Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by TRACON Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Tragara Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Trillium Therapeutics Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Verastem Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by VioQuest Pharmaceuticals Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Xbrane Biopharma AB, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ZIOPHARM Oncology Inc, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, H1 2017 (Contd..2), H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, H1 2017 (Contd..3), H1 2017

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports